Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders within the United States. The company's product pipeline features AXS-05, which is intended for treating major depressive disorder and resistant depression disorders. Currently, AXS-05 is undergoing a Phase III clinical trial aimed at addressing agitation associated with Alzheimer's disease and has also completed a Phase II clinical trial related to smoking cessation. Additionally, Axsome is advancing AXS-07, a novel, oral medication known for its rapid absorption and multi-mechanistic approach, having completed two Phase III trials for acute migraine treatment. AXS-12 is another investigational product, a selective and potent norepinephrine reuptake inhibitor currently in Phase III trials for narcolepsy treatment, while AXS-14, an oral investigational drug, is also in Phase III for fibromyalgia. Moreover, Axsome Therapeutics has established a research collaboration with Duke University to evaluate the efficacy of AXS-05 in smoking cessation. The company has shown significant financial growth, as evidenced by the recorded revenue of $385,693,000.00 demonstrating a steady upward trajectory. The income before tax ratio is -0.74 reflecting the pre-tax margin, while the net income ratio stands at -0.74 indicating the company's profitability margin. However, operating expenses amount to $632,952,000.00 which encompass various costs incurred for operations. Overall, the total costs and expenses for the company reach $666,255,000.00 illustrating its comprehensive spending in pursuit of its goals. In the context of market performance, Axsome Therapeutics' stock is reasonably priced at $116.69 making it attractive to a diverse range of investors. Despite this, the stock has a low average trading volume of 909,513.00 signaling a lower level of market activity. The company maintains a mid-range market capitalization of $5,687,508,602.00 positioning it as a steady performer within the industry. As a key player in the Biotechnology industry, Axsome Therapeutics contributes significantly to the broader market landscape, reinforcing its relevance and impact. Additionally, it belongs to the Healthcare sector, driving both innovation and growth in the field, thereby ensuring its sustained presence in an evolving market.